These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36940432)

  • 1. Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives.
    Xie Y; Yue L; Shi Y; Su X; Gan C; Liu H; Xue T; Ye T
    J Med Chem; 2023 Apr; 66(7):4342-4360. PubMed ID: 36940432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
    Knipe RS; Tager AM; Liao JK
    Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3.
    Li Q; Cheng Y; Zhang Z; Bi Z; Ma X; Wei Y; Wei X
    Clin Transl Med; 2022 Oct; 12(10):e1036. PubMed ID: 36178087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.
    Bei Y; Hua-Huy T; Duong-Quy S; Nguyen VH; Chen W; Nicco C; Batteux F; Dinh-Xuan AT
    Pulm Pharmacol Ther; 2013 Dec; 26(6):635-43. PubMed ID: 23928001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The functional role of rho and rho-associated coiled-coil forming protein kinase in eotaxin signaling of eosinophils.
    Adachi T; Vita R; Sannohe S; Stafford S; Alam R; Kayaba H; Chihara J
    J Immunol; 2001 Oct; 167(8):4609-15. PubMed ID: 11591790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rho Kinases and Cardiac Remodeling.
    Shimizu T; Liao JK
    Circ J; 2016 Jun; 80(7):1491-8. PubMed ID: 27251065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ROCK signaling in health, malignant and non-malignant diseases.
    Shahbazi R; Baradaran B; Khordadmehr M; Safaei S; Baghbanzadeh A; Jigari F; Ezzati H
    Immunol Lett; 2020 Mar; 219():15-26. PubMed ID: 31904392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis.
    Shimizu Y; Dobashi K; Iizuka K; Horie T; Suzuki K; Tukagoshi H; Nakazawa T; Nakazato Y; Mori M
    Am J Respir Crit Care Med; 2001 Jan; 163(1):210-7. PubMed ID: 11208648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striking crosstalk of ROCK signaling with endothelial function.
    Noma K; Kihara Y; Higashi Y
    J Cardiol; 2012 Jul; 60(1):1-6. PubMed ID: 22607993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.
    Feng Y; LoGrasso PV; Defert O; Li R
    J Med Chem; 2016 Mar; 59(6):2269-300. PubMed ID: 26486225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different regions of Rho determine Rho-selective binding of different classes of Rho target molecules.
    Fujisawa K; Madaule P; Ishizaki T; Watanabe G; Bito H; Saito Y; Hall A; Narumiya S
    J Biol Chem; 1998 Jul; 273(30):18943-9. PubMed ID: 9668072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening.
    Yu B; Sladojevic N; Blair JE; Liao JK
    Expert Opin Ther Targets; 2020 Jan; 24(1):47-62. PubMed ID: 31906742
    [No Abstract]   [Full Text] [Related]  

  • 13. ROCKs as therapeutic targets in cardiovascular diseases.
    Rikitake Y; Liao JK
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):441-51. PubMed ID: 15889972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction.
    Nagatoya K; Moriyama T; Kawada N; Takeji M; Oseto S; Murozono T; Ando A; Imai E; Hori M
    Kidney Int; 2002 May; 61(5):1684-95. PubMed ID: 11967018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulatory roles of ROCK and MRCK kinases in the plasticity of cancer cell migration.
    Kale VP; Hengst JA; Desai DH; Amin SG; Yun JK
    Cancer Lett; 2015 Jun; 361(2):185-96. PubMed ID: 25796438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis.
    Moriyama T; Nagatoya K
    Drug News Perspect; 2004; 17(1):29-34. PubMed ID: 14993932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges.
    Hu E; Lee D
    Expert Opin Ther Targets; 2005 Aug; 9(4):715-36. PubMed ID: 16083339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis.
    Knipe RS; Probst CK; Lagares D; Franklin A; Spinney JJ; Brazee PL; Grasberger P; Zhang L; Black KE; Sakai N; Shea BS; Liao JK; Medoff BD; Tager AM
    Am J Respir Cell Mol Biol; 2018 Apr; 58(4):471-481. PubMed ID: 29211497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
    Jacobs M; Hayakawa K; Swenson L; Bellon S; Fleming M; Taslimi P; Doran J
    J Biol Chem; 2006 Jan; 281(1):260-8. PubMed ID: 16249185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity.
    Monceau V; Pasinetti N; Schupp C; Pouzoulet F; Opolon P; Vozenin MC
    Curr Drug Targets; 2010 Nov; 11(11):1395-404. PubMed ID: 20583978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.